Long Term Metabolic and Inflammatory Effects of Second-Generation Antipsychotics: A Study in Mentally Disordered Offenders

被引:6
|
作者
Vassilopoulou, Emilia [1 ]
Efthymiou, Dimitris [2 ]
Papatriantafyllou, Evangelia [1 ]
Markopoulou, Maria [3 ]
Sakellariou, Efthymia-Maria [4 ]
Popescu, Alina Codruta [5 ]
机构
[1] Int Hellen Univ, Dept Nutr Sci & Dietet, Thessaloniki 57400, Greece
[2] Aristotle Univ Thessaloniki, Sch Med, Div Neurosci, Dept Psychiat, Thessaloniki 54124, Greece
[3] Psychiat Hosp Thessaloniki, Dept Forens Psychiat, Thessaloniki 56429, Greece
[4] Gen Univ Hosp, Psychiat Clin, Larisa 41110, Greece
[5] Iuliu Hatieganu Univ Med & Pharm, Dept Abil Human Sci, Cluj Napoca 400012, Romania
来源
JOURNAL OF PERSONALIZED MEDICINE | 2021年 / 11卷 / 11期
关键词
forensic psychiatry; antipsychotic drugs; metabolic disturbances; WEIGHT-GAIN; CARDIOMETABOLIC RISK; 1ST-EPISODE SCHIZOPHRENIA; DRUGS; ANTIDEPRESSANTS; ZIPRASIDONE; OLANZAPINE; QUETIAPINE; CLOZAPINE; LEPTIN;
D O I
10.3390/jpm11111189
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Mentally disordered offenders provided with forensic psychiatric care are often treated with second generation antipsychotic (SGA) medication and experience metabolic and inflammatory side effects. Aim: In this paper, we monitored the three-year fluctuation of selected anthropometric, biochemical, and inflammatory indices in forensic psychiatric patients receiving antipsychotic (AP) medication for more than five years, according to the type of AP. Methods: Thirty-five patients with psychotic disorders were classified into two groups based on the type of AP. Specifically: AP1, related to a lower risk, and AP2, related to an increased risk of weight gain (WG) and metabolic complications. Biochemical, hematological, anthropometric, blood pressure (BP), and medication data were retrieved from the individual medical files. Statistical analysis was performed with SPSS 23. Results: No significant differences in weight and glucose and cholesterol levels were observed, but patients taking AP2 more often needed drugs to control diabetes mellitus (DM), lipidemia, and cardiovascular disease (CVD). In those taking AP1, the mean HDL level decreased significantly over time (p < 0.05) and a higher proportion developed higher BP (52.9% of AP1 vs. 16.7% AP2). In the AP2 group the median level of C-reactive protein (CRP) (p < 0.001) and the white blood cell count (WBC) increased over the three years (p < 0.001). Conclusions: The proposed sub-classification of SGAs into AP1 and AP2, depending on their potential for metabolic and inflammatory effects, might facilitate study of their long-term side-effects but also help in personalized prevention or treatment measures to counteract these side-effects.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Effects of second-generation antipsychotics on human subcutaneous adipose tissue metabolism
    Sarsenbayeva, Assel
    Marques-Santo, Catia M.
    Thombare, Ketan
    Di Nunzio, Giada
    Almby, Kristina E.
    Lundqvist, Martin
    Eriksson, Jan W.
    Pereira, Maria J.
    PSYCHONEUROENDOCRINOLOGY, 2019, 110
  • [22] Lithium or Valproate Adjunctive Therapy to Second-generation Antipsychotics and Metabolic Variables in Patients With Schizophrenia or Schizoaffective Disorder
    Vincenzi, Brenda
    Greene, Claire M.
    Ulloa, Melissa
    Parnarouskis, Lindsey
    Jackson, John W.
    Henderson, David C.
    JOURNAL OF PSYCHIATRIC PRACTICE, 2016, 22 (03) : 175 - 182
  • [23] Practical guidelines for the use of long-acting injectable second-generation antipsychotics
    Jarema, Marek
    Wichniak, Adam
    Dudek, Dominika
    Samochowiec, Jerzy
    Bienkowski, Przemyslaw
    Rybakowski, Janusz
    PSYCHIATRIA POLSKA, 2015, 49 (02) : 225 - 241
  • [24] Metabolic Monitoring for Youths Initiating Use of Second-Generation Antipsychotics, 2003-2011
    Connolly, John G.
    Toomey, Timothy J.
    Schneeweiss, Maria C.
    PSYCHIATRIC SERVICES, 2015, 66 (06) : 604 - 609
  • [25] Metabolic Impairments Precede Changes in Hunger and Food Intake Following Short-Term Administration of Second-Generation Antipsychotics
    Teff, Karen L.
    Rickels, Karl
    Alshehabi, Erica
    Rickels, Michael R.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2015, 35 (05) : 579 - 582
  • [26] Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): Rationale, objectives, design and sample description
    Pina-Camacho, Laura
    Diaz-Caneja, Covadonga M.
    Saiz, Pilar A.
    Bobes, Julio
    Corripio, Iluminada
    Grasa, Eva
    Rodriguez-Jimenez, Roberto
    Fernandez, Miryam
    Sanjuan, Julio
    Garcia-Lopez, Aurelio
    Tapia-Casellas, Cecilia
    Alvarez-Blazquez, Maria
    Fraguas, David
    Mitjans, Marina
    Arias, Barbara
    Arango, Celso
    REVISTA DE PSIQUIATRIA Y SALUD MENTAL, 2014, 7 (04): : 166 - 178
  • [27] Enhancing metabolic monitoring for children and adolescents using second-generation antipsychotics
    Coughlin, Mary
    Goldie, Catherine L.
    Tregunno, Deborah
    Tranmer, Joan
    Kanellos-Sutton, Marina
    Khalid-Khan, Sarosh
    INTERNATIONAL JOURNAL OF MENTAL HEALTH NURSING, 2018, 27 (03) : 1188 - 1198
  • [28] Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses
    Moreno, Carmen
    Merchan-Naranjo, Jessica
    Alvarez, Mar
    Baeza, Inmaculada
    Alda, Jose A.
    Martinez-Cantarero, Carmen
    Parellada, Mara
    Sanchez, Bernardo
    de la Serna, Elena
    Giraldez, Marisa
    Arango, Celso
    BIPOLAR DISORDERS, 2010, 12 (02) : 172 - 184
  • [30] Long-Term Metabolic Effects in French-Canadian Children and Adolescents Treated with Second-Generation Antipsychotics in Monotherapy or Polytherapy: A 24-Month Descriptive Retrospective Study
    Ilies, Drigissa
    Huet, Anne-Sophie
    Lacourse, Eric
    Roy, Genevieve
    Stip, Emmanuel
    Ben Amor, Leila
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2017, 62 (12): : 827 - 836